SAN FRANCISCO, Calif., July 13, 2026
Universal Brain has achieved a significant regulatory milestone after receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for its UB ERP System, an innovative brain-function measurement platform designed to transform psychiatric care and central nervous system (CNS) drug development. The newly cleared technology combines the company’s proprietary dry-electrode electroencephalography (EEG) wearable with its Neurotique™ event-related potential (ERP) software to provide rapid, objective assessments of brain function in less than five minutes. The FDA clearance marks an important step toward integrating neuroscience-based biomarkers into routine psychiatric practice, where diagnosis and treatment have traditionally depended on subjective symptom evaluations and trial-and-error medication selection. By enabling clinicians to directly measure neural responses associated with cognitive and emotional processing, Universal Brain aims to improve diagnostic precision, personalize treatment decisions, and accelerate the development of next-generation therapies for mental health disorders. The milestone also strengthens the growing role of digital neurotechnology in advancing precision medicine for psychiatry and neurological diseases.
FDA Clearance Brings Objective Brain Measurement to Psychiatry
The UB ERP System introduces a streamlined approach to brain-function assessment by replacing traditional complex EEG procedures with a rapid, clinician-friendly platform capable of delivering analyzed results within minutes. Utilizing a proprietary dry-electrode EEG headset and advanced ERP analytics, the platform objectively measures neural activity during standardized cognitive and emotional tasks, providing valuable insights into how an individual patient’s brain is functioning. Unlike conventional psychiatric evaluations that rely heavily on behavioral observations and patient-reported symptoms, Universal Brain’s technology offers quantifiable neurophysiological data that can support diagnosis, treatment selection, and ongoing monitoring of therapeutic response. The company believes objective biomarkers will significantly improve the management of psychiatric disorders while reducing uncertainty associated with current treatment approaches. The FDA clearance establishes the platform as an important innovation capable of bringing neuroscience directly into everyday clinical practice and expanding opportunities for evidence-based mental healthcare.
Clinical Studies Advance Precision Psychiatry and CNS Drug Development
Following the FDA authorization, Universal Brain has initiated two multicenter clinical studies to further validate its platform in patients with depression. In the United States, the company is collaborating with Adams Clinical sites in Boston and New York to evaluate brain function before and after first-line antidepressant treatment with the goal of identifying biomarkers predictive of therapeutic response. A parallel 24-week longitudinal study in Japan will assess objective brain-function changes following treatment initiation across leading hospitals. Together, these studies are expected to generate valuable datasets supporting the development of precision psychiatry, enabling physicians to better predict treatment outcomes and optimize individualized care. The company has also appointed Dr. K. Luan Phan, Chair of Psychiatry at The Ohio State University College of Medicine, as Chief Medical Advisor, further strengthening its scientific leadership in psychiatric neuroscience and biomarker development.
Advertisement
Commercial Expansion Supports the Future of Mental Healthcare
In addition to its FDA milestone, Universal Brain has secured a $2 million grant from the Japan Agency for Medical Research and Development (AMED) under its Next-Generation Medical Device Development Project, providing support for multi-site clinical validation and commercialization activities. The company is preparing for a commercial launch later this year while continuing to build large-scale datasets that will expand the platform’s capabilities across multiple psychiatric and neurological conditions. Beyond supporting routine clinical care, the technology is expected to play an increasingly important role in CNS drug development, where objective brain-function biomarkers can improve patient selection, monitor therapeutic efficacy, and accelerate clinical research. By combining rapid EEG acquisition with advanced neuroscience analytics, Universal Brain is positioning itself at the forefront of precision psychiatry, helping move mental healthcare beyond symptom-based treatment toward objective, personalized, and data-driven clinical decision-making.
Source: Universal Brain press release
